NRG
KMTS

Nemes Rush Group’s Kestra Medical Technologies KMTS Stock Holding History

Nemes Rush Group’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Buy
+900
New +$18.8K ﹤0.01% 469

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Nemes Rush Group's KMTS Position: Q2 2026 in Review

Nemes Rush Group opened a new position in Kestra Medical Technologies (KMTS) in Q2 2026: 900 shares worth $22.9K. The stake represents ﹤0.01% of the portfolio and ranks #469 among its holdings.

109 funds tracked by Wall St. Rank hold KMTS as of Q2 2026.

  • Nemes Rush Group held 900 shares of Kestra Medical Technologies worth $22.9K as of Q2 2026.
  • Kestra Medical Technologies was a new Nemes Rush Group position in Q2 2026.
  • Kestra Medical Technologies made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #469 holding.
  • 109 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.